Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan

por Tsuchiya, Yumi, Tamura, Hiroshi, Fujii, Koji, Numaguchi, Hirotaka, Toyoizumi, Kiichiro, Liu, Tina, Le Gars, Mathieu, Cárdenas, Vicky, Eto, Takashi
Publicado 2023

CytoGLMM: conditional differential analysis for flow and mass cytometry experiments

por Seiler, Christof, Ferreira, Anne-Maud, Kronstad, Lisa M., Simpson, Laura J., Le Gars, Mathieu, Vendrame, Elena, Blish, Catherine A., Holmes, Susan
Publicado 2021

Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID‐19 vaccine Ad26.COV2.S in humans

por Dari, Anna, Jacqmin, Philippe, Iwaki, Yuki, Neyens, Martine, Le Gars, Mathieu, Sadoff, Jerald, Hardt, Karin, Ruiz‐Guiñazú, Javier, Pérez‐Ruixo, Juan José
Publicado 2023

Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine( )

por Le Gars, Mathieu, Sadoff, Jerald, Struyf, Frank, Heerwegh, Dirk, Truyers, Carla, Hendriks, Jenny, Gray, Glenda, Grinsztejn, Beatriz, Goepfert, Paul A, Schuitemaker, Hanneke, Douoguih, Macaya
Publicado 2022

Quantifying Antibody Persistence After a Single Dose of COVID‐19 Vaccine Ad26.COV2.S in Humans Using a Mechanistic Modeling and Simulation Approach

por Dari, Anna, Boulton, Muriel, Neyens, Martine, Le Gars, Mathieu, Valenzuela, Belén, Shukarev, Georgi, Cárdenas, Vicky, Ruiz‐Guiñazú, Javier, Sadoff, Jerald, Hoetelmans, Richard M. W., Ruixo, Juan José Pérez
Publicado 2022

LB7. Ad26.COV2.S-Elicted Neutralizing Activities Against SARS-CoV-2 Variants of Concern in Phase 1/2a and Phase 3 Clinical Trials

por Le Gars, Mathieu, Sadoff, Jerald, Jongeneelen, Mandy, Heerwegh, Dirk, Shukarev, Georgi, Truyers, Carla, de Groot, Anne Marit, Scheper, Gert, Hendriks, Jenny, Brandenburg, Boerries, Struyf, Frank, Van Hoof, Johan, Douoguih, Macaya, Schuitemaker, Hanneke
Publicado 2021

Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in in...

por Ong-Lim, Anna Lisa, Shukarev, Georgi, Trinidad-Aseron, Mitzi, Caparas-Yu, Delia, Greijer, Astrid, Duchene, Michel, Scheper, Gert, van Paassen, Vitalija, Le Gars, Mathieu, Cahill, Conor P., Schuitemaker, Hanneke, Douoguih, Macaya, Jacquet, Jeanne-Marie
Publicado 2022

Pregnancy-Induced Alterations in NK Cell Phenotype and Function

por Le Gars, Mathieu, Seiler, Christof, Kay, Alexander W., Bayless, Nicholas L., Starosvetsky, Elina, Moore, Lindsay, Shen-Orr, Shai S., Aziz, Natali, Khatri, Purvesh, Dekker, Cornelia L., Swan, Gary E., Davis, Mark M., Holmes, Susan, Blish, Catherine A.
Publicado 2019

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 tr...

por Hardt, Karin, Vandebosch, An, Sadoff, Jerald, Le Gars, Mathieu, Truyers, Carla, Lowson, David, Van Dromme, Ilse, Vingerhoets, Johan, Kamphuis, Tobias, Scheper, Gert, Ruiz-Guiñazú, Javier, Faust, Saul N, Spinner, Christoph D, Schuitemaker, Hanneke, Van Hoof, Johan, Douoguih, Macaya, Struyf, Frank
Publicado 2022

Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19

por Barouch, Dan H., Stephenson, Kathryn E., Sadoff, Jerald, Yu, Jingyou, Chang, Aiquan, Gebre, Makda, McMahan, Katherine, Liu, Jinyan, Chandrashekar, Abishek, Patel, Shivani, Le Gars, Mathieu, de Groot, Anne Marit, Heerwegh, Dirk, Struyf, Frank, Douoguih, Macaya, van Hoof, Johan, Schuitemaker, Hanneke
Publicado 2021

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination

por Barouch, Dan H., Stephenson, Kathryn E., Sadoff, Jerald, Yu, Jingyou, Chang, Aiquan, Gebre, Makda, McMahan, Katherine, Liu, Jinyan, Chandrashekar, Abishek, Patel, Shivani, Le Gars, Mathieu, de Groot, Anne M., Heerwegh, Dirk, Struyf, Frank, Douoguih, Macaya, van Hoof, Johan, Schuitemaker, Hanneke
Publicado 2021

Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials

por Sadoff, Jerald, Le Gars, Mathieu, Brandenburg, Boerries, Cárdenas, Vicky, Shukarev, Georgi, Vaissiere, Nathalie, Heerwegh, Dirk, Truyers, Carla, de Groot, Anne Marit, Jongeneelen, Mandy, Kaszas, Krisztian, Tolboom, Jeroen, Scheper, Gert, Hendriks, Jenny, Ruiz-Guiñazú, Javier, Struyf, Frank, Van Hoof, Johan, Douoguih, Macaya, Schuitemaker, Hanneke
Publicado 2022

SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques

por Roozendaal, Ramon, Solforosi, Laura, Stieh, Daniel J., Serroyen, Jan, Straetemans, Roel, Dari, Anna, Boulton, Muriel, Wegmann, Frank, Rosendahl Huber, Sietske K., van der Lubbe, Joan E. M., Hendriks, Jenny, Le Gars, Mathieu, Dekking, Liesbeth, Czapska-Casey, Dominika N., Guimera, Nuria, Janssen, Sarah, Tete, Sarah, Chandrashekar, Abishek, Mercado, Noe B., Yu, Jingyou, Koudstaal, Wouter, Perez-Ruixo, Juan J., Sadoff, Jerry, Barouch, Dan H., Schuitemaker, Hanneke, Zahn, Roland
Publicado 2021

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

por Sadoff, Jerald, Gray, Glenda, Vandebosch, An, Cárdenas, Vicky, Shukarev, Georgi, Grinsztejn, Beatriz, Goepfert, Paul A., Truyers, Carla, Van Dromme, Ilse, Spiessens, Bart, Vingerhoets, Johan, Custers, Jerome, Scheper, Gert, Robb, Merlin L., Treanor, John, Ryser, Martin F., Barouch, Dan H., Swann, Edith, Marovich, Mary A., Neuzil, Kathleen M., Corey, Lawrence, Stoddard, Jeffrey, Hardt, Karin, Ruiz-Guiñazú, Javier, Le Gars, Mathieu, Schuitemaker, Hanneke, Van Hoof, Johan, Struyf, Frank, Douoguih, Macaya
Publicado 2022

Durability of Heterologous and Homologous COVID-19 Vaccine Boosts

por Tan, C. Sabrina, Collier, Ai-ris Y., Yu, Jingyou, Liu, Jinyan, Chandrashekar, Abishek, McMahan, Katherine, Jacob-Dolan, Catherine, He, Xuan, Roy, Vicky, Hauser, Blake M., Munt, Jennifer E., Mallory, Michael L., Mattocks, Melissa, Powers, John M., Meganck, Rita M., Rowe, Marjorie, Hemond, Rachel, Bondzie, Esther A., Jaegle, Kate H., Baric, Ralph S., Schmidt, Aaron G., Alter, Galit, Le Gars, Mathieu, Sadoff, Jerald, Barouch, Dan H.
Publicado 2022

Comparative analysis of spike-specific IgG Fc glycoprofiles elicited by adenoviral, mRNA, and protein-based SARS-CoV-2 vaccines

por Van Coillie, Julie, Pongracz, Tamas, Šuštić, Tonći, Wang, Wenjun, Nouta, Jan, Le Gars, Mathieu, Keijzer, Sofie, Linty, Federica, Cristianawati, Olvi, Keijser, Jim B.D., Visser, Remco, van Vught, Lonneke A., Slim, Marleen A., van Mourik, Niels, Smit, Merel J., Sander, Adam, Schmidt, David E., Steenhuis, Maurice, Rispens, Theo, Nielsen, Morten A., Mordmüller, Benjamin G., Vlaar, Alexander P.J., Ellen van der Schoot, C., Roozendaal, Ramon, Wuhrer, Manfred, Vidarsson, Gestur
Publicado 2023

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

por Sadoff, Jerald, Le Gars, Mathieu, Shukarev, Georgi, Heerwegh, Dirk, Truyers, Carla, de Groot, Anne M., Stoop, Jeroen, Tete, Sarah, Van Damme, Wim, Leroux-Roels, Isabel, Berghmans, Pieter-Jan, Kimmel, Murray, Van Damme, Pierre, de Hoon, Jan, Smith, William, Stephenson, Kathryn E., De Rosa, Stephen C., Cohen, Kristen W., McElrath, M. Juliana, Cormier, Emmanuel, Scheper, Gert, Barouch, Dan H., Hendriks, Jenny, Struyf, Frank, Douoguih, Macaya, Van Hoof, Johan, Schuitemaker, Hanneke
Publicado 2021

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

por Sadoff, Jerald, Gray, Glenda, Vandebosch, An, Cárdenas, Vicky, Shukarev, Georgi, Grinsztejn, Beatriz, Goepfert, Paul A., Truyers, Carla, Fennema, Hein, Spiessens, Bart, Offergeld, Kim, Scheper, Gert, Taylor, Kimberly L., Robb, Merlin L., Treanor, John, Barouch, Dan H., Stoddard, Jeffrey, Ryser, Martin F., Marovich, Mary A., Neuzil, Kathleen M., Corey, Lawrence, Cauwenberghs, Nancy, Tanner, Tamzin, Hardt, Karin, Ruiz-Guiñazú, Javier, Le Gars, Mathieu, Schuitemaker, Hanneke, Van Hoof, Johan, Struyf, Frank, Douoguih, Macaya
Publicado 2021

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

por Alter, Galit, Yu, Jingyou, Liu, Jinyan, Chandrashekar, Abishek, Borducchi, Erica N., Tostanoski, Lisa H., McMahan, Katherine, Jacob-Dolan, Catherine, Martinez, David R., Chang, Aiquan, Anioke, Tochi, Lifton, Michelle, Nkolola, Joseph, Stephenson, Kathryn E., Atyeo, Caroline, Shin, Sally, Fields, Paul, Kaplan, Ian, Robins, Harlan, Amanat, Fatima, Krammer, Florian, Baric, Ralph S., Le Gars, Mathieu, Sadoff, Jerald, de Groot, Anne Marit, Heerwegh, Dirk, Struyf, Frank, Douoguih, Macaya, van Hoof, Johan, Schuitemaker, Hanneke, Barouch, Dan H.
Publicado 2021

Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters

por Tostanoski, Lisa H., Chandrashekar, Abishek, Patel, Shivani, Yu, Jingyou, Jacob-Dolan, Catherine, Chang, Aiquan, Powers, Olivia C., Sellers, Daniel, Gardner, Sarah, Barrett, Julia, Sanborn, Owen, Stephenson, Kathryn E., Ansel, Jessica L., Jaegle, Kate, Seaman, Michael S., Porto, Maciel, Lok, Megan, Spence, Brittany, Cayer, Kathleen, Nase, Danielle, Holman, Shaikim, Bradette, Heath, Kar, Swagata, Andersen, Hanne, Lewis, Mark G., Cox, Freek, Tolboom, Jeroen T. B. M., de Groot, Anne Marit, Heerwegh, Dirk, Le Gars, Mathieu, Sadoff, Jerald, Wegmann, Frank, Zahn, Roland C., Schuitemaker, Hanneke, Barouch, Dan H.
Publicado 2022